Gut microbiota in antipsychotic-naive patients with glucose-lipid metabolism disorders before and after first exposure to second-generation antipsychotics

Second-generation antipsychotics (SGAs) are first-line treatments for schizophrenia but are frequently associated with adverse metabolic effects, including dysregulation of glucose and lipid homeostasis. The underlying mechanisms remain incompletely understood. This study empolys an intergrated multiomics approach, combining 16S rRNA gene amplicon sequencing of fecal microbiota, to investigate the early impact of initial SGA exposure on the gut microbiome in antipsychotic-naive patients with schizophrenia.A self-controlled before-after design was implemented: stool samples were collected from medication-free patients at baseline (pre-medication, B group, n = 15) and after 3 months of SGA treatment (post-medication, n = 15). High-throughput sequencing revealed significant shifts in gut microbial composition follwing SGA initiation, including increased abundances of Escherichia and Bifidobacterium, and decreased levels of beneficial genera such as Faecalibacterium and Blautia.This BioProject encompasses the 16S rRNA sequencing data generated from paired fecal samples, which may inform future strategies for microbiota-targeted metabolic side effects. This study supports the article entitled "First exposure to second-generation antipsychotics alters gut microbiota and metabolic profiles in patients with glucose-lipid metabolism disorders" and is supported by Dalian Medical Science Reaserch Plan (No. 2111012).